DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT04733508

GLP1R-T2D

UnknownPhase NA

Glucagon Like Peptide 1 Receptor (GLP1R) Expression and Beta-cell Mass in Patients With Type 2 Diabetes

Glucagon Like Peptide 1 Receptor (GLP1R) Expression and Beta-cell Mass in Patients With Type 2 Diabetes - the Role of Glucose Homeostasis on Uptake of Beta-cell Tracer Exendin-4

Asset

Exenatide

GLP-1 agonist

Listed sites

1

Recruiting sites

1

Enrollment

28

estimated

Study population

Type 2 diabetes

Key I/E criterion

—

Primary endpoints

•Pancreatic exendin uptake 111In-DTPA exendin-4•Beta cell function•Blood glucose levels

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT04733508
Org study IDNL63933.091.17

Timeline

Milestones

Study start2019-11-01actual
Study first posted2021-02-02actual
Last update posted2021-02-02actual
Primary completion2022-06-01estimated
Study completion2022-12-01estimated

Assets

Investigational agents

Exenatide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Scheduled for partial or complete pancreatectomy at Radboudumc

Exclusion criteria

•Previous treatment with synthetic exendin or dipeptidyl-peptidase IV inhibitors within the past 3 months
•Breast feeding
•Pregnancy or the wist to become pregnant within 6 months
•Creatinine clearance below 40ml/min
•Liver disease defined as aspartate aminotransferase of alanine aminotransferase level of more than three times the upper limit of normal range

Endpoints (7)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)
4
Glycemic / diabetes
3

Glycemic / diabetes

3 endpoints
Primary/protocol endpoint/low confidence

Beta cell function

Time frame:The glucose tolerance test will be performed within a week before planned surgery

descriptive

Primary/protocol endpoint/low confidence

Blood glucose levels

Time frame:Blood glucose levels will be continuously monitored a week prior to surgery

descriptive, improvement

Primary/protocol endpoint

HbA1C levels

Time frame:HbA1C levels will be determined within a week before planned surgery

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Other (unclassified)

4 endpoints
Primary/protocol endpoint/low confidence

Pancreatic exendin uptake 111In-DTPA exendin-4

Time frame:111In-DTPA-exendin-4 injection will be performed a day before planned surgery, and uptake will be determined using ex vivo SPECTof the resected tissue one day after surgery

descriptive

Primary/protocol endpoint/low confidence

Pancreatic exendin uptake 111In-DTPA exendin-4

Time frame:111In-DTPA-exendin-4 injection will be performed a day before planned surgery, and uptake will be determined with tissue autoradiography immediately after resection

descriptive

Primary/protocol endpoint/low confidence

Pancreatic exendin uptake IRDye800CW-exendin-4

Time frame:IRDye800CW-exendin-4 injection will be performed a day before planned surgery, and uptake will be determined using microscopy in the excised tissue

descriptive

Primary/protocol endpoint/low confidence

Gene expression

Time frame:Gene expression will be determined in the excised pancreatic tissue immediately after resection

descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.